https://www.selleckchem.com/products/Eloxatin.html
[ Zr]Zr-DFO*-NCS-trastuzumab and [ Zr]Zr-DFO*Sq-trastuzumab showed excellent stability in vitro, superior to their [ Zr]Zr-DFO counterparts under all conditions. While tumour uptake was similar for all conjugates, bone uptake was lower for DFO* conjugates. Lower bone uptake for DFO* conjugates was confirmed using a second xenograft model A431 combined with cetuximab. Finally, in the intratibial BT-474 bone metastasis model, the DFO* conjugates provided superior detection of tumour-specific signal over the DFO conjugates. DFO*-mAb conju
Me gusta
Comentario
Compartir
